NO325178B1 - Rekonstituert human anti-HM1.24 antistoff og H-kjede derav, DNA som koder for V-regionen til H-kjeden og L-kjeden av antistoffet, vektor som omfatter nevnte DNA, vertcelle som omfatter nevnte vektor, fremgangsmate for produksjon av antistoffet, samt farmasoytisk blanding og terapeutisk middel som inneholder antistoffet. - Google Patents

Rekonstituert human anti-HM1.24 antistoff og H-kjede derav, DNA som koder for V-regionen til H-kjeden og L-kjeden av antistoffet, vektor som omfatter nevnte DNA, vertcelle som omfatter nevnte vektor, fremgangsmate for produksjon av antistoffet, samt farmasoytisk blanding og terapeutisk middel som inneholder antistoffet. Download PDF

Info

Publication number
NO325178B1
NO325178B1 NO19991591A NO991591A NO325178B1 NO 325178 B1 NO325178 B1 NO 325178B1 NO 19991591 A NO19991591 A NO 19991591A NO 991591 A NO991591 A NO 991591A NO 325178 B1 NO325178 B1 NO 325178B1
Authority
NO
Norway
Prior art keywords
antibody
chain
human
region
dna
Prior art date
Application number
NO19991591A
Other languages
English (en)
Norwegian (no)
Other versions
NO991591L (no
NO991591D0 (no
Inventor
Kosaka Masaaki
Ono Koichiro
Ohtomo Toshihiko
Tsuchiya Masayuki
Yoshimura Yasushi
Koishihara Yasuo
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of NO991591D0 publication Critical patent/NO991591D0/no
Publication of NO991591L publication Critical patent/NO991591L/no
Publication of NO325178B1 publication Critical patent/NO325178B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
NO19991591A 1996-10-04 1999-03-31 Rekonstituert human anti-HM1.24 antistoff og H-kjede derav, DNA som koder for V-regionen til H-kjeden og L-kjeden av antistoffet, vektor som omfatter nevnte DNA, vertcelle som omfatter nevnte vektor, fremgangsmate for produksjon av antistoffet, samt farmasoytisk blanding og terapeutisk middel som inneholder antistoffet. NO325178B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP26475696 1996-10-04
PCT/JP1997/003553 WO1998014580A1 (en) 1996-10-04 1997-10-03 Reconstituted human anti-hm1.24 antibody

Publications (3)

Publication Number Publication Date
NO991591D0 NO991591D0 (no) 1999-03-31
NO991591L NO991591L (no) 1999-06-01
NO325178B1 true NO325178B1 (no) 2008-02-11

Family

ID=17407753

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19991591A NO325178B1 (no) 1996-10-04 1999-03-31 Rekonstituert human anti-HM1.24 antistoff og H-kjede derav, DNA som koder for V-regionen til H-kjeden og L-kjeden av antistoffet, vektor som omfatter nevnte DNA, vertcelle som omfatter nevnte vektor, fremgangsmate for produksjon av antistoffet, samt farmasoytisk blanding og terapeutisk middel som inneholder antistoffet.

Country Status (19)

Country Link
US (2) US6699974B2 (de)
EP (1) EP0960936B1 (de)
KR (1) KR100388256B1 (de)
CN (2) CN1765928A (de)
AT (1) ATE512224T1 (de)
AU (1) AU715156B2 (de)
BR (1) BR9712488A (de)
CA (1) CA2267072C (de)
CZ (1) CZ296790B6 (de)
IL (1) IL129286A0 (de)
NO (1) NO325178B1 (de)
PL (1) PL187642B1 (de)
RU (1) RU2184147C2 (de)
SK (1) SK44399A3 (de)
TR (1) TR199900722T2 (de)
TW (1) TW530064B (de)
UA (1) UA76934C2 (de)
WO (1) WO1998014580A1 (de)
ZA (1) ZA978865B (de)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9811094A (pt) 1997-02-12 2000-07-18 Chugai Pharmaceutical Co Ltd Agente terapêutico para tumores linfáticos
AU718463B2 (en) * 1997-02-28 2000-04-13 Chugai Seiyaku Kabushiki Kaisha Inhibitor of lymphocyte activation
CA2308007C (en) 1997-10-14 2011-05-17 Chugai Seiyaku Kabushiki Kaisha Enhancer for antibody to lymphocytic tumors
WO1999043703A1 (fr) * 1998-02-25 1999-09-02 Chugai Seiyaku Kabushiki Kaisha Technique de dosage immunochimique de l'anticorps anti-hm1.24
WO2000017395A1 (fr) 1998-09-18 2000-03-30 Chugai Seiyaku Kabushiki Kaisha Procede de detection ou de mesure de plasmocytomes
CN1182244C (zh) 1999-05-10 2004-12-29 中外制药株式会社 培养细胞的方法
KR20020025990A (ko) 1999-08-23 2002-04-04 나가야마 오사무 에이치엠1.24 항원의 발현 증강제
AU2001246846A1 (en) * 2000-04-06 2001-10-23 Chugai Seiyaku Kabushiki Kaisha Immunoassay of anti-hm1.24 antibody
US8632778B2 (en) 2000-08-11 2014-01-21 Chugai Seiyaku Kabushiki Kaisha Stabilized anti-interleukin-6 antibody-containing preparations
JP4450555B2 (ja) * 2000-12-28 2010-04-14 協和発酵キリン株式会社 新規モノクローナル抗体
JP3986439B2 (ja) 2001-02-07 2007-10-03 中外製薬株式会社 造血器腫瘍の治療剤
EP3088412B1 (de) 2001-03-09 2021-05-05 Chugai Seiyaku Kabushiki Kaisha Proteinaufreinigungsverfahren
JP2005508838A (ja) * 2001-03-23 2005-04-07 アフトン コーポレーション 膵癌の組合せ治療
WO2002084290A1 (fr) * 2001-04-13 2002-10-24 Chugai Seiyaku Kabushiki Kaisha Procede permettant de quantifier l'expression d'antigenes
US20090191232A1 (en) * 2001-05-04 2009-07-30 Gevas Philip C Combination therapy for the treatment of tumors
CA2451493C (en) * 2001-06-22 2016-08-23 Chugai Seiyaku Kabushiki Kaisha Cell growth inhibitors containing anti-glypican 3 antibody
JP2004536835A (ja) * 2001-07-09 2004-12-09 アフトン コーポレーション 肝臓、肺および食道の癌性ならびに前癌性状態の治療および防止
AU2003211990A1 (en) 2002-02-14 2003-09-04 Chugai Seiyaku Kabushiki Kaisha Antibody-containing solution pharmaceuticals
US20080219974A1 (en) * 2002-03-01 2008-09-11 Bernett Matthew J Optimized antibodies that target hm1.24
EP1513879B1 (de) * 2002-06-03 2018-08-22 Genentech, Inc. Bibliotheken synthetischer antikörperphagen
EP1541165A4 (de) 2002-08-27 2009-06-24 Chugai Pharmaceutical Co Ltd Verfahren zur stabilisierung einer proteinl sungszubereitung
ES2558303T3 (es) 2002-09-11 2016-02-03 Chugai Seiyaku Kabushiki Kaisha Método de purificación de proteínas
JP4689597B2 (ja) * 2003-03-28 2011-05-25 レセプター バイオロジックス インク． ガストリンホルモン免疫アッセイ
CA2534055A1 (en) * 2003-08-01 2005-02-10 Genentech, Inc. Antibody cdr polypeptide sequences with restricted diversity
EP1666501A4 (de) 2003-08-11 2008-12-24 Chugai Pharmaceutical Co Ltd Zuckerkettenmodifizierter anti-hm1.24-antikörper
EP1693069B1 (de) * 2003-10-10 2013-07-24 Chugai Seiyaku Kabushiki Kaisha Mittel zur behandlung von soliden tumoren
ES2672640T3 (es) 2003-11-05 2018-06-15 Roche Glycart Ag Moléculas de unión a antígeno con afinidad de unión a receptores Fc y función efectora incrementadas
AU2005214382B2 (en) * 2004-02-19 2011-08-04 Genentech, Inc. CDR-repaired antibodies
EP1730193A2 (de) * 2004-03-29 2006-12-13 Receptor Biologix, Inc. Monoklonale antikörper gegen gastrinhormon
KR101333168B1 (ko) 2004-09-22 2013-11-28 리셉터 바이오로직스 인크 프로가스트린에 대한 모노클로날 항체
AU2012216702B2 (en) * 2005-08-26 2014-12-04 Roche Glycart Ag Modified antigen binding molecules with altered cell signaling activity
CA2619298C (en) * 2005-08-26 2017-07-04 Glycart Biotechnology Ag Modified antigen binding molecules with altered cell signaling activity
EP1957531B1 (de) 2005-11-07 2016-04-13 Genentech, Inc. Bindungspolypeptide mit diversifizierten und konsensus-vh/vl-hypervariablen sequenzen
WO2007064919A2 (en) * 2005-12-02 2007-06-07 Genentech, Inc. Binding polypeptides with restricted diversity sequences
US9084777B2 (en) 2005-12-28 2015-07-21 Chugai Seiyaku Kabushiki Kaisha Stabilized antibody-containing formulations
WO2008036688A2 (en) * 2006-09-18 2008-03-27 Xencor, Inc. Optimized antibodies that target hm1.24
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
EP2473531A4 (de) * 2009-09-03 2013-05-01 Merck Sharp & Dohme Anti-gitr-antikörper
AR080428A1 (es) 2010-01-20 2012-04-11 Chugai Pharmaceutical Co Ltd Formulaciones liquidas estabilizadas contentivas de anticuerpos
US9574005B2 (en) 2011-07-19 2017-02-21 Chugai Seiyaku Kabushiki Kaisha Stable Protein-containing preparation containing argininamide or analogous compound thereof
KR101993488B1 (ko) 2011-09-01 2019-06-26 추가이 세이야쿠 가부시키가이샤 한외여과에 의해 고도로 농축된 항체를 포함하는 조성물의 제조 방법
BR112016014824A2 (pt) 2013-12-27 2017-09-19 Chugai Pharmaceutical Co Ltd Método para purificar anticorpo que tem ponto isoelétrico baixo
JP6858559B2 (ja) 2014-08-20 2021-04-14 中外製薬株式会社 蛋白質溶液の粘度測定方法
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
WO2018232230A1 (en) 2017-06-15 2018-12-20 Cancer Advances Inc. Compositions and methods for inducing humoral and cellular immunities against tumors and cancer
US12150978B2 (en) 2017-06-15 2024-11-26 Cancer Advances Inc. Compositions and methods for preventing tumors and cancer
CN109748964B (zh) * 2017-11-01 2020-11-17 深圳宾德生物技术有限公司 CD317单链抗体317scFv、其编码序列及制备方法和应用
CA3096222A1 (en) 2018-04-06 2019-10-10 Atyr Pharma, Inc. Compositions and methods comprising anti-nrp2 antibodies
CN112512480B (zh) 2018-05-21 2024-10-01 中外制药株式会社 被封入玻璃容器的冷冻干燥制剂
CN112243423B (zh) 2018-05-28 2022-11-04 中外制药株式会社 填充喷嘴
CN114746120B (zh) * 2019-10-03 2024-07-30 Atyr医药公司 包含抗nrp2抗体的组合物和方法
TW202333781A (zh) 2021-10-08 2023-09-01 日商中外製藥股份有限公司 抗ｈｌａ－ｄｑ２﹒５抗體製劑
KR20240102971A (ko) 2021-11-16 2024-07-03 제넨테크, 인크. 모수네투주맙을 이용하여 전신 홍반성 루푸스(sle)를 치료하기 위한 방법과 조성물
TW202400262A (zh) 2022-04-26 2024-01-01 日商中外製藥股份有限公司 含有醫藥製劑的內含過濾器之注射器
EP4696321A1 (de) 2023-04-14 2026-02-18 Chugai Seiyaku Kabushiki Kaisha Verfahren zur stabilisierung einer proteinhaltigen pharmazeutischen zubereitung

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO873164L (no) * 1986-07-30 1988-02-01 Teijin Ltd Muse-humane kimaere antistoffer.
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
GB9014932D0 (en) * 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
EP0628639B1 (de) 1991-04-25 1999-06-23 Chugai Seiyaku Kabushiki Kaisha Rekombinierte humane antikörper gegen den humanen interleukin 6-rezeptor
ES2251723T3 (es) * 1994-08-12 2006-05-01 Immunomedics, Inc. Inmunoconjugados y anticuerpos humanizados especificos para linfoma de celulas b y celulas de leucemia.
BR9811094A (pt) * 1997-02-12 2000-07-18 Chugai Pharmaceutical Co Ltd Agente terapêutico para tumores linfáticos
US20020034507A1 (en) * 1997-02-28 2002-03-21 Yasuo Koishihara Inhibitor of lymphocyte activation
JP3992298B2 (ja) * 1997-10-03 2007-10-17 中外製薬株式会社 天然ヒト型化抗体
CA2308007C (en) * 1997-10-14 2011-05-17 Chugai Seiyaku Kabushiki Kaisha Enhancer for antibody to lymphocytic tumors
ES2263984T3 (es) * 2002-06-28 2006-12-16 Domantis Limited Ligandos doble-especificos con una vida media serica aumentada.

Also Published As

Publication number Publication date
PL332742A1 (en) 1999-10-11
EP0960936B1 (de) 2011-06-08
CN1765928A (zh) 2006-05-03
CZ117399A3 (cs) 1999-09-15
CA2267072A1 (en) 1998-04-09
US7892543B2 (en) 2011-02-22
NO991591L (no) 1999-06-01
CA2267072C (en) 2004-11-30
WO1998014580A1 (en) 1998-04-09
TR199900722T2 (xx) 1999-12-21
BR9712488A (pt) 1999-10-19
IL129286A0 (en) 2000-02-17
HK1024261A1 (en) 2000-10-05
CZ296790B6 (cs) 2006-06-14
EP0960936A1 (de) 1999-12-01
SK44399A3 (en) 2000-05-16
EP0960936A4 (de) 2005-01-19
US20030129185A1 (en) 2003-07-10
KR100388256B1 (ko) 2003-06-19
UA76934C2 (en) 2006-10-16
ZA978865B (en) 1998-04-20
AU715156B2 (en) 2000-01-20
CN1235639A (zh) 1999-11-17
TW530064B (en) 2003-05-01
PL187642B1 (pl) 2004-08-31
KR20000048884A (ko) 2000-07-25
US6699974B2 (en) 2004-03-02
CN1271205C (zh) 2006-08-23
NO991591D0 (no) 1999-03-31
AU4399297A (en) 1998-04-24
ATE512224T1 (de) 2011-06-15
US20030045691A1 (en) 2003-03-06
RU2184147C2 (ru) 2002-06-27

Similar Documents

Publication Publication Date Title
NO325178B1 (no) Rekonstituert human anti-HM1.24 antistoff og H-kjede derav, DNA som koder for V-regionen til H-kjeden og L-kjeden av antistoffet, vektor som omfatter nevnte DNA, vertcelle som omfatter nevnte vektor, fremgangsmate for produksjon av antistoffet, samt farmasoytisk blanding og terapeutisk middel som inneholder antistoffet.
US7052873B2 (en) Natural human antibody
FI108917B (fi) Menetelmä terapeuttisesti käyttökelpoisten CD4-spesifisen yhdistelmävasta-aineen valmistamiseksi
US7332582B2 (en) Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
JPWO1999018212A1 (ja) 天然ヒト型化抗体
US20130071385A1 (en) Monoclonal antibodies
JP3587664B2 (ja) 再構成ヒト抗ｈｍ１．２４抗体
JP3587843B2 (ja) 再構成ヒト抗ｈｍ１．２４抗体
AU725867B2 (en) Reconstituted human anti-HM1.24 antibody
JP4115425B2 (ja) 再構成ヒト抗ｈｍ１．２４抗体
HK1023366A (en) Reconstituted human anti-hm1.24 antibody
AU2009288700B2 (en) Monoclonal antibodies
HK1029372A (en) Natural human antibody